On May 15, 2017 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a late-stage clinical biopharmaceutical company developing topsalysin (PRX302) as a first-in-class treatment for urological diseases, reported that successful data from its Phase 2a proof-of-concept study of topsalysin, which evaluated the drug as a focal treatment for localized prostate cancer, will be presented today as a poster at the 112th AUA meeting (Press release, Sophiris Bio, MAY 15, 2017, View Source [SID1234519127]). Schedule your 30 min Free 1stOncology Demo! Abstract Title: "Intra-Prostatic Injection of PRX302 Focal Therapy in Treating Clinically Significant Low-Intermediate Risk Prostate Cancer: An Open Label, Proof-of-Concept Study"
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presenting Author: Edward J. Bass, University College London, London, UK
Poster Session: MP70: Prostate Cancer: Localized: Ablative Therapy 1
Time: May 15, 2017 from 7:00 a.m. – 9:00 a.m. ET
The poster will be available on the Company’s website at www.sophirisbio.com.